← Back to patent-cliff list
Antarelix
Tier C — Watch / tradeAntarelix
COSCIENS Biopharma Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：GnRH
Indications (approved)：Urinary retention, Benign prostatic hyperplasia, Prostate cancer
Regional status
US
-
EU
Phase II
2021-03-04
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Antarelix?
Approved indications include: Urinary retention, Benign prostatic hyperplasia, Prostate cancer.
When does the Antarelix patent expire?
No public expiry year is available for Antarelix yet; this page updates once verified.
How do I get a quote for Antarelix intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21